SecBot SecBot
8-K ·Filed Jul 8, 2026

MDAI

Spectral AI, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed3mo ago SEC0001213900-26-076349
8-K context-dependent: Items 5.02, 7.01
Actionable Insight • Neutral

This is a routine C-suite hire signaling the company's shift to commercialization post-FDA clearance. Monitor for first sales announcements and the next quarterly report for revenue trajectory. No immediate trading catalyst.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
MDAI ▼ -3.49% at T+60d
NEUTRAL call -3.49% · α vs SPY -5.12% · entry $1.72 → $1.66
Entry = T+0 close
Jul 8, 2026
via day close
T+1d
0.00%
call 0.00% · α -0.43%
$1.72
settled 4mo ago
T+5d
-4.07%
call -4.07% · α -3.94%
$1.65
settled 3mo ago
T+20d
-3.49%
call -3.49% · α -5.73%
$1.66
settled 3mo ago
T+60d
-3.49%
call -3.49% · α -5.12%
$1.66
settled 26d ago

Price Chart

Loading chart...

Executive Summary

Spectral AI appointed Darcy Bajko as Chief Commercial Officer, effective July 31, 2026, to lead the commercial launch of its FDA-cleared DeepView System for burn indication. This is a key executive hire as the company transitions from product development to commercial execution, but no financial figures or guidance changes were provided in the filing.

Key Facts

  • Darcy Bajko appointed Chief Commercial Officer, effective July 31, 2026.
  • Bajko will oversee the global launch of the FDA-cleared DeepView System for burn indication (De Novo clearance in May 2026).
  • Bajko receives $315,000 annual base salary, up to 30% bonus, and 150,000 stock options vesting over 3 years.
  • CEO Vincent Capone stated the company's near-term priority is closing first commercial sales by year-end 2026.
  • No financial results, guidance, or material agreements other than the offer letter were disclosed.

Financial Impact

No financial impact disclosed. Bajko's compensation: $315,000 annual salary, up to 30% bonus, 150,000 option grant.

Risk Factors

  • No disclosed revenue or commercial traction yet — execution risk on first sales by year-end 2026.
  • Small market cap ($55M) with no financial details in this filing — limited near-term data.
  • Warrant overhang (MDAIW) could dilute if exercised, though no exercise activity mentioned.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-076349
Document: ea0297412-8k_spectral.htm0001213900-26-076349
Document: ea029741201ex99-2.htm0001213900-26-076349
Document: 0001213900-26-076349-index-headers.html0001213900-26-076349
Document: 0001213900-26-076349-index.html0001213900-26-076349
Document: 0001213900-26-076349.txt0001213900-26-076349
5 reports for MDAI
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for MDAI — sortable, filterable
TypeNow
Aug 12, 2026
10w ago
8-K
NEUTRAL ★ 5/10
$1.73awaiting T+60—$1.50 (−13.29%)
Jul 8, 2026
15w ago
8-K
NEUTRAL ★ 4/10
$1.72 $1.66▼ −3.49%▼ −5.12%$1.50 (−12.79%)
Mar 24, 2026
30w ago
Press Release
MIXED ★ 6/10
$1.54 $1.76▲ +14.15%▲ +0.69%$1.50 (−2.60%)
Mar 18, 2026
31w ago
Press Release
BULLISH ★ 8/10
$1.42 $1.84▲ +29.58%▲ +15.23%$1.50 (+5.63%)
Mar 10, 2026
32w ago
Press Release
NEUTRAL ★ 3/10
$1.40 $1.94▲ +38.57%▲ +26.89%$1.50 (+7.14%)
Showing 5 of 5

US Market Status

Market Closed — Opens in 8h 11m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 8, 2026